News

Losing tiny bile ducts in the liver (ductopenia) could be a strong warning sign of worse outcomes in people with PBC.

People with primary biliary cholangitis (PBC) who do not receive treatment face much higher medical costs than those who are treated.

Genetic analyses indicate that PBC directly increases the risk of lacunar stroke, suggesting a causal relationship.

Compared to healthy controls, patients with early-stage PBC have altered expression of a class of molecules known as sphingolipids.

Second-line therapies in PBC can change the lives of patients for the better if they provide adequate symptomatic control.

Complement proteins could potentially be used to diagnose PBC, predict risk of PBC and spot patients who may develop serious liver damage.

People living with PBC were found to be significantly more likely to have blood type A compared to people without autoimmune liver disease.

Treatment for primary biliary cholangitis (PBC) needs to be personalized when the first standard medicine does not work well enough.

A group of 151 experts convened to develop a set of recommendations for primary biliary cholangitis (PBC) treatment and care.

Researchers highlight progress in gut-targeted therapies for PBC